vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and CPI Card Group Inc. (PMTS). Click either name above to swap in a different company.
CPI Card Group Inc. is the larger business by last-quarter revenue ($153.1M vs $83.5M, roughly 1.8× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs 4.8%, a 2.0% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 22.3%). CPI Card Group Inc. produced more free cash flow last quarter ($35.2M vs $6.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
CPI Card Group Inc. is a leading provider of payment card production and associated solutions, including contactless and contact credit/debit cards, prepaid cards, and card personalization services. It primarily serves financial institutions, fintech firms, and retail brands across its core North American market.
BLLN vs PMTS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $153.1M |
| Net Profit | $5.7M | $7.3M |
| Gross Margin | 69.9% | 31.5% |
| Operating Margin | 11.5% | 12.0% |
| Net Margin | 6.8% | 4.8% |
| Revenue YoY | 117.4% | 22.3% |
| Net Profit YoY | 138.3% | 8.5% |
| EPS (diluted) | $0.10 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $153.1M | ||
| Q3 25 | $83.5M | $138.0M | ||
| Q2 25 | — | $129.8M | ||
| Q1 25 | — | $122.8M | ||
| Q4 24 | — | $125.1M | ||
| Q3 24 | $38.4M | $124.8M | ||
| Q2 24 | — | $118.8M | ||
| Q1 24 | — | $111.9M |
| Q4 25 | — | $7.3M | ||
| Q3 25 | $5.7M | $2.3M | ||
| Q2 25 | — | $518.0K | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | $6.8M | ||
| Q3 24 | $-14.9M | $1.3M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | — | $5.5M |
| Q4 25 | — | 31.5% | ||
| Q3 25 | 69.9% | 29.7% | ||
| Q2 25 | — | 30.9% | ||
| Q1 25 | — | 33.2% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | 52.6% | 35.8% | ||
| Q2 24 | — | 35.7% | ||
| Q1 24 | — | 37.1% |
| Q4 25 | — | 12.0% | ||
| Q3 25 | 11.5% | 9.4% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 11.5% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | -32.9% | 14.3% | ||
| Q2 24 | — | 12.5% | ||
| Q1 24 | — | 12.6% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | 6.8% | 1.7% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | -38.8% | 1.0% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | — | 4.9% |
| Q4 25 | — | $0.62 | ||
| Q3 25 | $0.10 | $0.19 | ||
| Q2 25 | — | $0.04 | ||
| Q1 25 | — | $0.40 | ||
| Q4 24 | — | $0.56 | ||
| Q3 24 | $-1.47 | $0.11 | ||
| Q2 24 | — | $0.51 | ||
| Q1 24 | — | $0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $21.7M |
| Total DebtLower is stronger | $55.0M | $286.7M |
| Stockholders' EquityBook value | $-239.5M | $-17.3M |
| Total Assets | $327.5M | $403.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $21.7M | ||
| Q3 25 | $195.2M | $16.0M | ||
| Q2 25 | — | $17.1M | ||
| Q1 25 | — | $31.5M | ||
| Q4 24 | — | $33.5M | ||
| Q3 24 | — | $14.7M | ||
| Q2 24 | — | $7.5M | ||
| Q1 24 | — | $17.1M |
| Q4 25 | — | $286.7M | ||
| Q3 25 | $55.0M | $308.4M | ||
| Q2 25 | — | $310.9M | ||
| Q1 25 | — | $280.7M | ||
| Q4 24 | — | $280.4M | ||
| Q3 24 | — | $280.2M | ||
| Q2 24 | — | $269.7M | ||
| Q1 24 | — | $265.3M |
| Q4 25 | — | $-17.3M | ||
| Q3 25 | $-239.5M | $-25.7M | ||
| Q2 25 | — | $-29.0M | ||
| Q1 25 | — | $-29.7M | ||
| Q4 24 | — | $-35.6M | ||
| Q3 24 | $-242.9M | $-42.8M | ||
| Q2 24 | — | $-44.6M | ||
| Q1 24 | — | $-48.5M |
| Q4 25 | — | $403.2M | ||
| Q3 25 | $327.5M | $407.1M | ||
| Q2 25 | — | $399.8M | ||
| Q1 25 | — | $351.9M | ||
| Q4 24 | — | $349.7M | ||
| Q3 24 | — | $342.3M | ||
| Q2 24 | — | $321.4M | ||
| Q1 24 | — | $319.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $39.6M |
| Free Cash FlowOCF − Capex | $6.5M | $35.2M |
| FCF MarginFCF / Revenue | 7.7% | 23.0% |
| Capex IntensityCapex / Revenue | 8.8% | 2.9% |
| Cash ConversionOCF / Net Profit | 2.42× | 5.39× |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $39.6M | ||
| Q3 25 | $13.8M | $10.0M | ||
| Q2 25 | — | $4.3M | ||
| Q1 25 | — | $5.6M | ||
| Q4 24 | — | $26.7M | ||
| Q3 24 | — | $12.5M | ||
| Q2 24 | — | $-4.8M | ||
| Q1 24 | — | $8.9M |
| Q4 25 | — | $35.2M | ||
| Q3 25 | $6.5M | $5.3M | ||
| Q2 25 | — | $533.0K | ||
| Q1 25 | — | $292.0K | ||
| Q4 24 | — | $21.6M | ||
| Q3 24 | — | $11.1M | ||
| Q2 24 | — | $-6.0M | ||
| Q1 24 | — | $7.4M |
| Q4 25 | — | 23.0% | ||
| Q3 25 | 7.7% | 3.8% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 17.3% | ||
| Q3 24 | — | 8.9% | ||
| Q2 24 | — | -5.0% | ||
| Q1 24 | — | 6.6% |
| Q4 25 | — | 2.9% | ||
| Q3 25 | 8.8% | 3.4% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 4.3% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | — | 5.39× | ||
| Q3 25 | 2.42× | 4.32× | ||
| Q2 25 | — | 8.39× | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | 3.94× | ||
| Q3 24 | — | 9.70× | ||
| Q2 24 | — | -0.79× | ||
| Q1 24 | — | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
PMTS
| US Debit And Credit | $128.9M | 84% |
| US Prepaid Debit | $24.4M | 16% |
